Catalog Products » LILRA4/CD85g, His & Avi, Human
Manual
Manual
COAs

LILRA4/CD85g, His & Avi, Human

LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain.LILRA4 function coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades.
$340.00
Z05587-100

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRA4/CD85g (Glu24-Asn446)_x000D_
Accession # P59901		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 49.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

LILRA4/CD85g, His & Avi, Human

The purity of LILRA4/CD85g, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »

LILRA4/CD85g, His & Avi, Human

LILRA4/CD85g, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%. »

<
>

Background
Target Background LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain.LILRA4 function coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354). Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades.
Synonyms CD85g; ILT7; ILT-7; ILT7MGC129598; LILRA4; MGC129597
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.